Gujarat-Based Pharma Company Unveils Promising Treatment for Diabetic Neuropathy

A breakthrough in the world of pharmaceuticals emerges from a Gujarat-based company, Asprius Lifesciences, as they unveil a potential game-changer in the treatment of diabetic neuropathy. This prevalent condition, affecting millions globally, leads to nerve damage in peripheral regions, resulting in numbing sensations, tingling, pain, and weakness in the extremities.

The innovative treatment, a fixed-dose combination (FDC) of two drugs, holds great promise and has already been patented by the company. Spearheaded by the visionary Chairman & MD, Vishal Zinzuwadia, and backed by the brilliant mind of Dr. Sanjay Agrawal, Medical Director of Asprius Lifesciences, this novel formulation offers new hope to those battling diabetic neuropathy.

Recognizing the severe impact of diabetic neuropathy on patients’ quality of life, the company is now diligently conducting clinical trials to assess the safety and efficacy of their revolutionary FDC. If successful, the treatment will soon be available in India, marking a significant milestone in the fight against this debilitating condition.

With the potential to mitigate symptoms and prevent further complications, this cutting-edge development signifies a crucial step forward in addressing diabetic neuropathy’s unmet medical needs. Asprius Lifesciences’ dedication to improving patients’ lives serves as a beacon of hope for countless individuals seeking relief from the burdens of diabetic neuropathy.